Worldwide patent granted for “High Concentration Protein Formulations with Reduced Viscosity”.

With this new patented technology that holds great potential as a "Platform" technology, BRL aims to help large and small biopharmaceutical companies achieve syringeable viscosities for high-concentration protein biologics like monoclonal antibodies. This will pave the way for low cost, low-volume subcutaneous monoclonal antibodies for the treatment of various cancers and autoimmune disorders.